[Comment to the study: experiences in the treatment of benign prostatic hyperplasia with high power potassium-titanyl-phosphate (KTP)].
Jeromin
Leszek M
LM
Klinika Urologii z Pracownia Litotrypsji, UM, Lodz, Poland
D006417:Hematuria / Q000209:etiology; D006801:Humans; D053685:Laser Therapy / Q000009:adverse effects / Q000379:methods*; D008297:Male; D010710:Phosphates / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000601:surgery*; D014025:Titanium / Q000627:therapeutic use*; D020728:Transurethral Resection of Prostate / Q000009:adverse effects / Q000379:methods*; D016055:Urinary Retention / Q000209:etiology
D010710:Phosphates; C064806:potassium titanylphosphate; D014025:Titanium